DSM reported that sales for its pharma-facing business unit fell to €178m in Q2 2011 from €195m in the same period in 2010 and H1 sales fell to €341m from €381m. The company said that its pharma sales and results improved compared to Q1, but it is conscious that overall performance of the cluster remains below acceptable levels. DSM attributed the lower Q2 sales to the weaker US dollar and lower volumes at DSM Pharmaceutical Products.
DSM
Tuesday 2 August 2011
DSM pharma sales slow
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment